Lingumelt

Loperamide Hydrochloride, the active ingredient in Lingumelt, is an opioid antidiarrheal presented as an oral formulation for oral use. It is employed to reduce the frequency and urgency of stools in acute nonspecific diarrhea, chronic diarrhea, and irritable bowel syndrome with diarrhea in adults. GNH USA supplies Lingumelt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lingumelt acts on the gastrointestinal tract to control excessive bowel movements associated with diarrheal disorders. Acute nonspecific diarrhea: reduces stool frequency and improves stool consistency. Chronic diarrhea: helps maintain regularity and decreases fluid loss. Irritable bowel syndrome with diarrhea (IBS‑D): alleviates urgency and abdominal discomfort.

Lingumelt may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Constipation - Abdominal cramps - Nausea - Dry mouth - Dizziness - Headache

Serious or Rare Side Effects: - Severe constipation or ileus - Toxic megacolon - Allergic reactions such as rash, swelling, or anaphylaxis - Cardiac arrhythmias including QT prolongation - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Central nervous system depression in overdose.

Before using Lingumelt, consider the following safety measures. - Assess hydration status: ensure adequate fluid replacement in patients with diarrhea. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid in children younger than 2 years: risk of severe constipation. - Do not exceed the recommended daily dose: higher doses increase the risk of cardiac toxicity. - Monitor for signs of constipation or abdominal distension during therapy. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Loperamide may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase loperamide plasma levels. - P‑glycoprotein inhibitors (e.g., quinidine, ritonavir): can raise systemic exposure. - Other antidiarrheal agents: additive effect on gut motility may cause severe constipation.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may enhance anticholinergic side effects. - Medications that prolong QT interval: concurrent use may increase arrhythmia risk. - Opioid analgesics: combined central opioid effects are unlikely but monitor for sedation.